Mersalyl

Summary

Mersalyl (CHEMBL1200943) is an approved small molecule (ATC C03BC01); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03BC01
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200943
Name	Mersalyl
Type	Small molecule
Max phase	4
ATC	C03BC01

Also known as: Mercuramide, Mersalilo, Mersalyl, Mersalyl sodium, Salyrgan, MERSALYL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).